Usted buscó: in vitro studies are inconclusive (Inglés - Croata)

in vitro studies
ispitivanja in vitro

in vitro inhibition studies
in vitro ispitivanja inhibicije

in vitro cyp p450 interaction studies
ispitivanja interakcije cyp p450 in vitro

in vitro studies with p-glycoprotein
in vitro ispitivanja s p-glikoproteinom

in vitro studies of antiviral activity
in vitro ispitivanja protuvirusnog djelovanja

in vitro studies of cyp and ugt inhibition and induction
in vitro ispitivanja inhibicije i indukcije cyp i ugt

desloratadine has demonstrated antiallergic properties from in vitro studies.
desloratadin je pokazao antialergijska svojstva u in vitro ispitivanjima.

in vitro studies indicate that asenapine weakly inhibits cyp2d6.
istraživanja in vitro ukazuju da je asenapin slab inhibitor cyp2d6.

in vitro studies indicated that axitinib inhibits p-glycoprotein.
ispitivanja in vitro ukazala su na to da aksitinib inhibira p-glikoprotein.

desloratadine has demonstrated anti-allergic properties from in vitro studies.
desloratadin je pokazao antialergijska svojstva u in vitro ispitivanjima.

additionally, in vitro studies suggest that ivacaftor may inhibit cyp2c9.
osim toga, in vitro ispitivanja ukazuju na to da ivakaftor može inhibirati cyp2c9.

based upon in vitro studies, the circulating metabolites of duloxetine are considered pharmacologically inactive.
na temelju in vitro ispitivanja, cirkulirajući metaboliti duloksetina smatraju se farmakološki neaktivnima.

in vitro studies have also indicated that eribulin is not a substrate for oct1.
ispitivanja in vitro pokazala su također da eribulin nije supstrat za oct1.

in in vitro studies, daptomycin was not metabolised by human liver microsomes.
u in vitro ispitivanjima daptomicin se nije metabolizirao putem mikrosoma ljudske jetre.

based on in vitro studies, osimertinib is a competitive inhibitor of bcrp transporters.
temeljeno na in vitro ispitivanjima, osimertinib je kompetitivni inhibitor bcrp transportera.

in vitro studies demonstrated that telaprevir is not an inhibitor of ugt1a9 or ugt2b7.
in vitro ispitivanja su pokazala da telaprevir ne inhibira ugt1a9 ili ugt2b7.

in vitro studies have shown that osimertinib is not a substrate of oatp1b1 and oatp1b3.
in vitro ispitivanja su pokazala da osimertinib nije supstrat oatp1b1 i oatp1b3.

in vitro studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome p450.
in vitro ispitivanja nisu dokazala da pioglitazon inhibira bilo koji podtip citokroma p450.

in vitro studies did not show any significant involvement of oxidative metabolism by cytochrome p450 enzymes.
in vitro ispitivanja nisu pokazala znatniji udio oksidacijskog metabolizma posredovanog enzimima citokroma p450 .

based on in vitro studies, carboxymethylenebutenolidase is involved in the hydrolysis in the intestine and liver.
na temelju ispitivanja in vitro, karboksimetilen- butenolidaza uključena je u hidrolizu u crijevima i jetri.